Warfarin is named as an intervention in 5 current clinical trials in our China, UK and USA registers. 3 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Hoffmann-La Roche (1). The most-studied condition is Active Ulcerative Colitis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
NCT05643651 · ClinicalTrials.gov ↗ · Kawasaki Disease, Coronary Artery Aneurysm
|
Phase 4 | Recruiting | Children's Hospital of Fudan University | China |
|
Low INR to Minimize Bleeding With Mechanical Valves Trial
NCT03636295 · ClinicalTrials.gov ↗ · Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement
|
Phase 3 | Recruiting | Population Health Research Institute | China |
|
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
NCT07665723 · ClinicalTrials.gov ↗ · Active Ulcerative Colitis
|
Phase 1 | Recruiting | Hoffmann-La Roche | UK, USA |
|
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
NCT07502001 · ClinicalTrials.gov ↗ · Overweight, Obesity
|
Phase 1 | Not yet open | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | China |
|
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
NCT07603700 · ClinicalTrials.gov ↗ · Pulmonary Embolism, Venous Thromboembolism
|
Observational | Not yet open | Nanjing First Hospital, Nanjing Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Hoffmann-La Roche | 1 |
| Nanjing First Hospital, Nanjing Medical University | 1 |
| Children's Hospital of Fudan University | 1 |
| Population Health Research Institute | 1 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 2 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China, UK and USA registers name Warfarin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 5 trials are recruiting: 2 with sites in China, 1 with sites in UK and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Hoffmann-La Roche (1), Nanjing First Hospital, Nanjing Medical University (1), Children's Hospital of Fudan University (1) and Population Health Research Institute (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Warfarin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Warfarin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Warfarin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.